This is a demo store. No orders will be fulfilled.

Pavurutamab , CAS No.2250292-39-6

In stock
Item Number
P648319
Grouped product items
SKU Size
Availability
Price Qty
P648319-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$625.90

Basic Description

Biochemical and Physiological Mechanisms Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab ( HY-P99798 ). The Fc of Pavurutamab is coupled to molecules to improv
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Product Description

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti- CD3 and anti- B cell maturation antigens ( BCMA ). Pavurutamab has an extended half-life based on Pacanalotamab . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)

In Vitro

Pavurutamab (0-10000 pM; 48 h) induces CD69 + , CD25 + T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models. Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs. Dosage: 0.02, 0.2 and 2 mg/kg. Administration: Intravenous injection; single dose on days 3, 8, 13. Result: Reduced tumor volume. Animal Model: NOD/SCID mice orthotopically transplanted with L-363 MM cells. Dosage: 0.005, 0.05 and 0.5 mg/kg. Administration: Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days. Result: Reduced tumor volume and increased survival.

IC50& Target:B cell maturation antigens, BCMA

Names and Identifiers

Smiles [Pavurutamab]

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.